163 related articles for article (PubMed ID: 11487547)
1. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.
González-Abraldes J; Albillos A; Bañares R; Del Arbol LR; Moitinho E; Rodríguez C; González M; Escorsell A; García-Pagán JC; Bosch J
Gastroenterology; 2001 Aug; 121(2):382-8. PubMed ID: 11487547
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.
Bañares R; Moitinho E; Matilla A; García-Pagán JC; Lampreave JL; Piera C; Abraldes JG; De Diego A; Albillos A; Bosch J
Hepatology; 2002 Dec; 36(6):1367-73. PubMed ID: 12447861
[TBL] [Abstract][Full Text] [Related]
3. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients.
Castaño G; Viudez P; Riccitelli M; Sookoian S
Ann Hepatol; 2003; 2(1):36-40. PubMed ID: 15094704
[TBL] [Abstract][Full Text] [Related]
4. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
Agasti AK; Mahajan AU; Phadke AY; Nathani PJ; Sawant P
J Dig Dis; 2013 May; 14(5):266-71. PubMed ID: 23280243
[TBL] [Abstract][Full Text] [Related]
5. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
Schneider AW; Kalk JF; Klein CP
Hepatology; 1999 Feb; 29(2):334-9. PubMed ID: 9918907
[TBL] [Abstract][Full Text] [Related]
6. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
Bishnu S; Ahammed SM; Sarkar A; Hembram J; Chatterjee S; Das K; Dhali GK; Chowdhury A; Das K
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):54-59. PubMed ID: 29099421
[TBL] [Abstract][Full Text] [Related]
7. Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis.
García-Pagán JC; Escorsell A; Feu F; Bandi JC; Moitinho E; Casado M; Bosch J; Rodés J
J Hepatol; 1996 Apr; 24(4):430-5. PubMed ID: 8738729
[TBL] [Abstract][Full Text] [Related]
8. Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
De BK; Bandyopadhyay K; Das TK; Das D; Biswas PK; Majumdar D; Mandal SK; Ray S; Dasgupta S
Am J Gastroenterol; 2003 Jun; 98(6):1371-6. PubMed ID: 12818283
[TBL] [Abstract][Full Text] [Related]
9. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity.
Baik SK; Park DH; Kim MY; Choi YJ; Kim HS; Lee DK; Kwon SO; Kim YJ; Park JW; Chang SJ
J Gastroenterol; 2003; 38(12):1150-4. PubMed ID: 14714252
[TBL] [Abstract][Full Text] [Related]
10. Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis.
Tripathi D; Therapondos G; Lui HF; Johnston N; Webb DJ; Hayes PC
Am J Gastroenterol; 2004 Feb; 99(2):390-4. PubMed ID: 15046234
[TBL] [Abstract][Full Text] [Related]
11. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects.
Morillas RM; Planas R; Cabré E; Galán A; Quer JC; Feu F; García Pagán JC; Bosch J; Gassull MA
Hepatology; 1994 Dec; 20(6):1502-8. PubMed ID: 7982651
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
13. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
Lin HC; Yang YY; Hou MC; Huang YT; Lee FY; Lee SD
Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome.
Piecha F; Mandorfer M; Peccerella T; Ozga AK; Poth T; Vonbank A; Seitz HK; Rausch V; Reiberger T; Mueller S
Am J Physiol Gastrointest Liver Physiol; 2018 Oct; 315(4):G484-G494. PubMed ID: 29746172
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
[TBL] [Abstract][Full Text] [Related]
16. Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis.
Schiedermaier P; Koch L; Stoffel-Wagner B; Layer G; Sauerbruch T
Aliment Pharmacol Ther; 2003 Oct; 18(8):777-84. PubMed ID: 14535870
[TBL] [Abstract][Full Text] [Related]
17. Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.
Schepke M; Wiest R; Flacke S; Heller J; Stoffel-Wagner B; Herold T; Ghauri M; Sauerbruch T
Am J Gastroenterol; 2008 May; 103(5):1152-8. PubMed ID: 18422814
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic prevention of variceal bleeding and rebleeding.
Baiges A; Hernández-Gea V; Bosch J
Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
[TBL] [Abstract][Full Text] [Related]
19. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function.
Albillos A; Lledó JL; Rossi I; Pérez-Páramo M; Tabuenca MJ; Bañares R; Iborra J; Garrido A; Escartín P; Bosch J
Gastroenterology; 1995 Oct; 109(4):1257-65. PubMed ID: 7557093
[TBL] [Abstract][Full Text] [Related]
20. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats.
Heller J; Shiozawa T; Trebicka J; Hennenberg M; Schepke M; Neef M; Sauerbruch T
Eur J Clin Invest; 2003 Nov; 33(11):1006-12. PubMed ID: 14636305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
